Drug intelligence / Profile preview

TJ086

Development stage: Preclinical
Lead developer: Tuojie Biotech
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

TJ086 is a preclinical-stage small interfering RNA (siRNA) therapeutic developed by Tuojie Biotech for the treatment of muscle diseases. The drug utilizes Tuojie's proprietary RNA interference (RNAi) technology and extrahepatic delivery platform to target and silence specific mRNA transcripts within muscle tissue. By reducing the production of proteins that drive muscle pathology, TJ086 aims to provide a targeted treatment for genetic or acquired muscular disorders. As of 2024, the program is in the Preclinical Candidate (PCC) stage of development.

Other names: TJ086TJ-086TJ 086

Targets

TTR (Transthyretin)

Beyond the preview

Go deeper on TJ086.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TJ086.

Explore the full profile